Clinical trials are an essential tool in modern medicine: they are research investigations in which people voluntarily participate in studies for new treatments and interventions to prevent, diagnose or manage blood disorders. Clinical trials are crucial for the development of new medical treatments and help determine if new medicines are effective, safe or better than the current treatments available and aim to answer the following questions in a controlled environment:
Does the treatment work? Is the treatment safe - does it have significant side effects? Is the treatment better that other treatments already available? If better, does it have less side effects? Does it work faster? Is it more cost-effective than other treatments?
Please visit participate in a clinical trial for details on how to participate in a trial, or contact us for further information. Summaries of PBI's previous clinical trials can be found in our archived projects; our current active clinical trials are listed below.
To learn more about participating in a clinical trial, read our new patient information booklet.
Read more
This study will evaluate Sapablursen in patients with polycythemia vera. Read more
This study is an open-label study of Povetacicept in subjects with autoimmune cytopenias. Read more
This is a study comparing Abelacimab to Dalteparin in the treatment of gastrointestinal/genitourinary cancer and associated venous thromboembolism. Read more
This study will compare treatment with Abelacimab to apixaban on venous thromboembolism recurrence and bleeding in patients with cancer associated VTE. Read more
This study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL). Read more
This study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants with diffuse large b-cell lymphoma. Read more
This study is to compare the efficacy and safety of pirtobruitinib to ibrutinib in participants with chronic lymphocytic leukaemia / small lympocytic lymphoma. Read more
This is an observational Cohort study to assess the immune response to the SARS-CoV-2 vaccination and the prevalence of clotting related antibodies in haematology and other immunosuppressed patients. Read more
A Phase 3 study comparing the efficacy and safety of IberDd versus DVd in participants with relapsed or refractory multiple myeloma (RRMM). Read more
A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia Read more
This is an open label, randomized, two-arm Phase 3 study in subjects with relapsed or refractory FL and MZL to evaluate efficacy and safety of zandelisib in combination with rituximab in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP). Read more
This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Read more
This study consists of two parts to explore BGB-16673 recommended dosing. Read more
This is an extension study to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Read more
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib. Read more
This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP. Read more
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Read more
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML) Read more
A phase 1/2a study to evaluate safety, pharmacokinetic and pharmacodynamic dose escalation and expansion study of PXS-5505 in patients with primary, postpolycythemia vera or post-essential thrombocythemia myelofibrosis Read more
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors. Read more
An observational study of patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network. Read more
Study the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with Atezolizumab in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Read more
Study of the safety, pharmacokinetics, and clinical activity of PRN1008, an oral BTK inhibitor, in patients with relapsed Immune Thrombocytopenic Purpura. Read more